TEM's diagnostics arm is surging on rising oncology demand, accelerated MRD adoption and higher pricing. Management signals 2026 growth should remain strong as broader sequencing use and expanding reimbursement underpin durable revenue and pricing power in diagnostics.
TEM's diagnostics arm is surging on rising oncology demand, accelerated MRD adoption and higher pricing. Management signals 2026 growth should remain strong as broader sequencing use and expanding reimbursement underpin durable revenue and pricing power in diagnostics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
